You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雙鷺藥業(002038.SZ)與新鄉化纖擬按持股比例共同對新鄉雙鷺增資3000萬元
格隆匯 01-08 17:59

格隆匯 1 月 8日丨雙鷺藥業(002038.SZ)公佈,公司202118日召開屆董事會第十六次臨時會議監事十二臨時會議審議通過《關於對控股子公新鄉雙鷺藥業有限公司增資暨關聯交易的議案》,同意公司與關聯股東新鄉化纖股份有限公司共同雙鷺藥業控股子公司新鄉雙鷺藥業有限公司(“新鄉雙鷺”)比例資。雙鷺藥業使用自有資金2100萬元人民幣認購新鄉雙鷺2100萬元註冊資本。

為滿足新鄉雙鷺持續發展需要,經雙鷺藥業(持有新鄉雙鷺70%股份)與新鄉化纖股份有限公司(新鄉化纖,持有新鄉雙鷺30%股份)協商,公司與新鄉化纖擬按持股比例共同對新鄉雙鷺增資3000萬元。其中,北京雙鷺藥業股份有限公司增資2100萬元,新鄉化纖股份有限公司增資900萬元。此次增資完成後,新鄉雙鷺註冊資本由6000萬元增至9000萬元,新鄉雙鷺仍為公司控股子公司,新鄉雙鷺各股東的持股比例保持不變。

公司獨立董事魏素豔、蘇志國對該事項進行了事前認可,並發表獨立意見如下:認為以上事項將進一步加強其原料藥基地的建設規模,為新鄉雙鷺後續原料藥上市後生產奠定資金基礎,有利於擴大生產規模。此關聯交易表決程序符合《公司法》和《公司章程》的規定,關聯董事已迴避表決,不涉及交易定價,未損害公司及其他股東,特別是中小股東的利益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account